AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06537115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: whey protein powder
Description: The protein intake is 60 grams per day, taken in three divided doses for 12 consecutive weeks. Attention should be paid to monitoring liver and kidney function, and the dosage of protein powder should be adjusted according to the condition of the patient.
Study NCT06537115 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Eldecalcitol
Description: Eldecalcitol soft gel capsules are taken at an oral dose of 0.75μg once a day for 12 consecutive weeks.
Study NCT05170711 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypotensive anesthesia
Description: hypotensive anesthesia
Study NCT05170711 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: normotensive anesthesia
Description: normotensive anesthesia group
Study NCT04822181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide administrated subcutaneously (under the skin) once weekly there will be a period of dose escalation before reaching the target dose.
Study NCT04822181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administrated subcutaneously (under the skin) once weekly.
Study NCT06141278 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care cascade intervention
Description: Co-designed integrated care based on the Chronic Care Model to improve hypertension and diabetes care cascade
Study NCT05105178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Giving orientation with headphones
Description: During emergence, recorded voice of an investigator giving Information of orientation (time, place, patient's own name) is repeatedly played from noise-cancelling headphones
Study NCT05105178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emergence as usual with headphones
Description: During emergence, recorded voice of an investigator calling the patient's name is repeatedly played from noise-cancelling headphones
Study NCT05970263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.
Description: 2 inhalations twice daily administered by oral inhalation, from a metered dose inhaler, over a 12-month follow-up period.
Study NCT05970263 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: External Comparator
Description: Received any inhaled therapy, excluding triple inhaled maintenance therapy, during index hospitalization and refilled within 30 days before or after discharge from index hospitalization
Study NCT06126237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 injection
Description: CM313, subcutaneous injection
Study NCT05099692 — intervention group
Intervention type: BEHAVIORAL
Intervention: filling out the questionnaire
Description: all participants in our study are invited to choose at least 1 question in 15 questions or provide their own questions regarding their doubt about the CR after filling in their personal information
Study NCT05010356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Hyperinsulinemic euglycemic clamp
Study NCT04949620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REThink therapeutic game
Description: REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
Study NCT06287034 — intervention group
Intervention type: PROCEDURE
Intervention: Primary suture
Description: The primary suture can be performed according to the different techniques available at the discretion of the surgeon (vertical, horizontal or T-shaped closure, with continuous suture, according to Connell or with detached stitches)
Study NCT05682027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound of the diaphragm
Description: Parameters measured during ultrasound:~Thickening fraction; End-expiratory thickness, and; Diaphragm excursion.
Study NCT04901910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) Social Media Group
Description: Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities and well-being. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
Study NCT04901910 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verdi plus PA Social Media Group
Description: Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities, well-being, and reducing risky behaviors. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
Study NCT06461260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nervio-X
Description: An 8-channel TIS device developed by NEURODOME Corporation.
Study NCT04864431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D capsules: each capsule contain 2 tablets of vitamin D 1000 IU. One capsule will be taken on day 1 through 180
Study NCT04864431 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule: Each capsule contain saccharum lactis. One capsule will be taken on day 1 through 180
Study NCT05276479 — intervention group
Intervention type: OTHER
Intervention: Anonymous online survey on dietary habits and mental health
Description: Assessment of regular feeding behavior and mental health
Study NCT05729412 — intervention group
Intervention type: OTHER
Intervention: Mentioned
Description: If prescription is properly filled for specific details than it is compliance
Study NCT06273332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-assisted registration
Description: We will use artificial intelligence to register 3d model on intra-oral scan
Study NCT06273332 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Point-based registration
Description: We will use five references points or more to perform model registration
Study NCT06410560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training about storytelling and creative writing: 12 hours
Description: Participants in training courses on creative writing and storytelling.
Study NCT06410560 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Training only about theoretical narrative medicine: 4 hours
Description: Participants in training courses on only theoretical narrative medicine.
Study NCT04872114 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
Description: Radiofrequency ablation of renal arterial sympathetic nerves
Study NCT05402423 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training plus aerobic exercise with the JDome System
Description: Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks).~Each session will involve the following activities:~* 30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia~* 30 minutes of aerobic training with the JDOME system,
Study NCT05402423 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computerized cognitive training plus aerobic exercise with standard exercise bike
Description: Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks).~Each session will involve the following activities:~* 30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia~* 30 minutes of aerobic training with standard exercise bike
Study NCT05875870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daylight exposure combine walking
Description: 1. Out-door of bright-light exposure in the morning (36 min/day, 7 times/week) for six weeks.~2. Tailored to the individual patient with moderate intensity of walking (3 sessions/week) for six weeks. Duration of each session depends on one-on-one exercise consultation via communication software (LINE App). The duration of walking in week 1 is 15 minutes, then increasing 5 minutes each week if the patient has tolerance. If the patient cannot tolerate the duration, the coach will instruct to keep the same duration for the following week. Basically, the goal of duration in week six is 40 minutes.~3. Weekly exercise consultation via communication software (LINE App).~4. Teaching strategy includes one-on one instruction (hard-copy of teaching manual), video, and webpage.
Study NCT05875870 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercise
Description: The stretching exercise includes two movements for the upper body and two movements for the lower body, 10 minutes each time, three times a week, for 6 weeks.~The researcher will explain to the participants about how to perform the stretching exercise, according to an instruction manual (hardcopy) for the exercise regimen.~A video is shown to the participants (the content same as hardcopy of education manual).
Study NCT04949620 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online parenting program
Description: The online parenting intervention consists of a newly developed parenting program, including rational emotive behavioral therapy and schema therapy principles
Study NCT05602688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lemon Balm Supplement
Description: Oral 200 mg Lemon Balm supplement tablet Twice a day for three-weeks
Study NCT05216965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW2821
Description: All subjects will receive a single intravenous (IV) infusion of 9MW2821 once weekly for the first 3 weeks of every 4 week cycle (i.e., on Days 1, 8 and 15).
Study NCT06081907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: IBI363 is based on the 3+3 model with a dose of 1 mg/kg Q3W. IBI325, 20 mg/kg Q3W.
Study NCT06081907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: IBI363 is based on the 3+3 model with a dose of 1.5 mg/kg Q3W. IBI325, 20 mg/kg Q3W.
Study NCT06081907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: IBI363 is based on the 3+3 model with a dose of 600 μg/kg Q2W. Lenvatinib, 8mg QD.
Study NCT06081907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: IBI363 is based on the 3+3 model with a dose of 1000 μg/kg Q2W. Lenvatinib, 8mg QD.
Study NCT06081907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI363
Description: The recommended dosages for IBI363, IBI325, and Lenvatinib in Phase Ib will be determined based on a comprehensive assessment of safety, efficacy, and other data obtained from the safety introduction portions of both Phase Ia (Part A) and Phase Ib (Part B).
Study NCT04539730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: 266 mg or 20 ml Liposomal Bupivacaine injectable solution
Study NCT04539730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drug: SoC Ropivacaine
Description: 0.5% (5mg/mL) 20 mL single dose SOC anesthetic Ropivacaine.
Study NCT04539730 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drug: SoC Ropivacaine
Description: 0.5% (5mg/mL) 20 mL single dose SOC anesthetic Ropivacaine.
Study NCT06494995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: a PD-1/CTLA-4 dual antibody
Study NCT05602688 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Matched Placebo
Description: Matched placebo tablet Twice a day for three-weeks
Study NCT04978649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allisartan Isoproxil
Description: Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
Study NCT04978649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Allisartan Isoproxil
Description: Allisartan Isoproxil 240mg daily will be used to lower BP to below 120 mm Hg systolic.
Study NCT04978649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
Study NCT04978649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amlodipine
Description: Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal (below 120 mm Hg systolic).
Study NCT06443307 — intervention group
Intervention type: DRUG
Intervention: Irinotecan Liposome
Description: The experimental group will collect data from patients treated with Nal-IRI as the chemotherapy regimen. It is recommended to use according to the label, clinical practice shall prevail.
Study NCT06494995 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-dose radiotherapy
Description: Low-dose radiation
Study NCT06494995 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: selected leisions to treat with stereotactic radiotherapy
Study NCT06494995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine metronomic chemotherapy
Study NCT05059314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brisk walking (moderate physical activity)
Description: 1. Warm up and cool down~2. Brisk walk (30 mintues each session per week 5 days)~3. Week 1 to 6
Study NCT05213091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme
Description: The first four weeks will be Otago Exercise Programme training and practice. For the next weeks, there will be institution visits and telephone interviews. Individuals will be given an Otago Exercise Programme training booklet, exercise chart and exercise diary to better manage this process. The research will be conducted in small groups (average 6-8).
Study NCT05422508 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG1111 (BARICELA)
Description: 0.5ml, single dose, subcutaneous injection
Study NCT05422508 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX
Description: 0.5ml, single dose, subcutaneous injection
Study NCT06501651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Description: Sacubitril/Valsartan is a novel antihypertensive medication composed of an angiotensin II receptor blocker (ARB) Valsartan and a neprilysin inhibitor Sacubitril in a 1:1 molar co-crystal form. Sacubitril is a prodrug that, once ingested, is metabolized by esterases into its active form, which inhibits neprilysin activity. Neprilysin has various substrates, including natriuretic peptides and angiotensin II (Ang II). By inhibiting neprilysin, the levels of natriuretic peptides that have antihypertensive and organ-protective effects are increased. The other component, Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing additional antihypertensive and organ-protective effects. The co-crystal structure ensures that Sacubitril and Valsartan have similar absorption and elimination rates, thereby synchronizing their pharmacological effects.
Study NCT06501651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing both antihypertensive and organ-protective effects.
Study NCT04754451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group L
Description: Attach two lidocaine patches for 12 hours, one above and below the incision site.
Study NCT05341271 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Experimental: digital reminiscence group (DRG)
Description: Experiment group A accepted the digital reminiscence group planned by the official account platform of line as the medium, the theme and content, it is planned to consider the development of the life cycle, and the experience of the thematic review will induce the motivation of the participants, since childhood life, study The design of eight unit themes such as stage, work and emotional family and festival life, and special life events; at the same time, it can adapt to the psychological adaptation behavior of the participants, review their life development stages according to the life development process, and pay attention to the interpersonal interaction carried out by the current group Negative emotional or symptomatic behavior with dialogue, and directing and dealing with life experiences
Study NCT05341271 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Experimental: general reminiscence group (GRG)
Description: Experiment group B participated in general reminiscence group (GRG)~, using actual nostalgic objects or utensils to carry out activities. The theme and content are intended to be considered in the context of life cycle development, and the experience of thematic retrospectives induces the motivation of participants, since childhood. The design of eight unit themes, including the stage of study, work and emotional family and festival life, and special events in life; at the same time, it can adapt to the psychological adaptation behavior of the participants, review their life development stages according to the life development process, and pay attention to the current group activities. Interpersonal interaction and dialogue, and negative emotional or symptomatic behaviors that guide and process life experiences
Study NCT05337254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine
Description: Dihydroergotamine intranasal powder
Study NCT05337254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroergotamine
Description: Dihydroergotamine intramuscular injection
Study NCT05337254 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroergotamine
Description: Dihydroergotamine intranasal spray
Study NCT06413862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofol
Description: The experimental group was slowly injected with ciprofol for 30 seconds (0.4mg/kg, Haisike Pharmaceutical Co., Ltd., Liaoning, China, batch number 20220911).
Study NCT06413862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: The control group was slowly injected with propofol for 30 seconds (2mg/kg, Guorui Pharmaceutical Co., Ltd., Sichuan, China, batch number 22102914).
Study NCT05707091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low level laser therapy and conventional therapy
Description: One group treated with low level laser therapy along with conventional therapy
Study NCT05707091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional therapy
Description: Group B treated with ems and exercises
Study NCT04852848 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect2Test Intervention
Description: Brief assessment based feedback and motivational interviewing intervention
Study NCT04852120 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Compound Sodium Picosulfate Granules administered by the patient prior to X-ray examination, endoscopy or surgery when judged clinically necessary in accordance to usual practice consistent with the local prescribing information.
Study NCT05217771 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High tone power therapy group
Description: patients in this group will receive High tone power therapy from 30 to 60 minutes, 3 session /week for 4 weeks with total sessions at least l0 sessions and self-stretch for hand and shoulder.
Study NCT05677074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil
Description: The tolerance of fish oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
Study NCT05677074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cod oil
Description: The tolerance of cod oil is tested using three methods: skin-prick-test, Basophil Histamine Release Assay, and oral provocation.
Study NCT05677074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Krill oil
Description: The tolerance of krill oil is tested using two methods: skin-prick-test and Basophil Histamine Release Assay. (We were unable to acquire enough liquid krill oil to perform oral provocation with this supplement).
Study NCT05104580 — intervention group
Intervention type: DEVICE
Intervention: Quantitative Flow Ratio derived PPG
Description: From coronary angiographic images, QFR will be calculated and virtual pullback curve will be abstracted and PPG index will be calculated as:~PPG index={MaxPPG20mm/△QFRvessel+(1-length with functional disease/Total vessel length) }/2.
Study NCT05879042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static Stretching
Description: Participants will be placed in the maximum dorsiflexion position of the ankle of the dominant side lower extremities. At this last point, it will be held in a static position for 30 seconds. A total of 10 repetitions will be done, with 5-10 seconds rest between repetitions.
Study NCT05879042 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic Stretching
Description: Participants will be positioned by placing their hands on the edge of the standing wall. They will be asked to try to increase normal ankle motion in a controlled manner using their own body weight. The stretching position will be held for 30 seconds and a total of 10 repetitions will be done. There will be 5-10 seconds rest between repetitions.